Publication:
Prognostic Factors Associated with Resected Osteosarcoma: Efficacy of Adjuvant Setting, Real-World Experience

Simple item page
dc.contributor.authorŞİMŞEK, FATİH
dc.contributor.authorSEVER, NADİYE
dc.contributor.authorKOCAASLAN, ERKAM
dc.contributor.authorEREL, PINAR
dc.contributor.authorARIKAN, RUKİYE
dc.contributor.authorSARI, MURAT
dc.contributor.authorBAYOĞLU, İBRAHİM VEDAT
dc.contributor.authorKÖSTEK, OSMAN
dc.contributor.authorsMajidova N., ŞİMŞEK F., Biter S., YASLIKAYA Ş., Seyyar M., DUYGULU M. E., Arcagok M., Kircali M. F., Sever N., KOCAASLAN E., et al.
dc.date.accessioned2024-06-10T15:19:18Z
dc.date.available2024-06-10T15:19:18Z
dc.date.issued2024-01-01
dc.description.abstractOsteosarcoma is a curable tumor. Surgery is performed after neoadjuvant chemotherapy as the primary standard treatment, followed by adjuvant therapy again. However, it is seen in patients who have undergone surgery without neoadjuvant chemotherapy. Adjuvant treatment is always given in this group. However, it is controversial how many cycles of adjuvant treatment should be given. In our study, 42 patients with osteosarcoma who received only adjuvant treatment without neoadjuvant treatment were analyzed for the effects of epidemiologic factors, treatment regimens on overall survival and disease-free survival. Retrospectively, 42 osteosarcoma patients (5 centers) with a current age of 18years and older who were followed up between 2001-2022 were examined. Twenty-five (60.0%) were below 8 cm, and 16 (38.0%) were 8 cm and above. The median number of cycles of adjuvant chemotherapy was 4 (range; 1-6). The 4-year DFS rate was 50.2%. In patients with primary tumors smaller and larger than 8cm, the 4-year DFS rates were 66.1% and 22.2%, respectively. The 4-year DFS rates for patients with 4 or less and more than 4 cycles of adjuvant chemotherapy were 27.1% and 69.2%, respectively. The 4-year OS rate was 78.5% in patients with primary tumors smaller than 8 cm and 18.8% in patients with tumors larger than 8 cm. The 4-year OS rate was 24.3% in patients who received 4 or less adjuvant cycles and 79.5% in patients who received more than 4 cycles. We have demonstrated that the number of adjuvant therapy courses above 4 and the presence of primary tumors smaller than 8 cm are influential over overall and disease-free survival in the patients who did not receive neoadjuvant therapy. The number of postoperative adjuvant treatment cycles should be forced as much as possible in these patients who haven’t had neoadjuvant therapy.
dc.identifier.citationMajidova N., ŞİMŞEK F., Biter S., YASLIKAYA Ş., Seyyar M., DUYGULU M. E., Arcagok M., Kircali M. F., Sever N., KOCAASLAN E., et al., "Prognostic Factors Associated with Resected Osteosarcoma: Efficacy of Adjuvant Setting, Real-World Experience", UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi, cilt.34, sa.1, ss.20-27, 2024
dc.identifier.doi10.4999/uhod.247419
dc.identifier.endpage27
dc.identifier.issn1306-133X
dc.identifier.issue1
dc.identifier.startpage20
dc.identifier.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85194152961&origin=inward
dc.identifier.urihttps://hdl.handle.net/11424/297030
dc.identifier.volume34
dc.language.isoeng
dc.relation.ispartofUHOD - Uluslararasi Hematoloji-Onkoloji Dergisi
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectTıp
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectHematoloji
dc.subjectOnkoloji
dc.subjectSağlık Bilimleri
dc.subjectMedicine
dc.subjectInternal Medicine Sciences
dc.subjectInternal Diseases
dc.subjectHematology
dc.subjectOncology
dc.subjectHealth Sciences
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectHEMATOLOJİ
dc.subjectONKOLOJİ
dc.subjectClinical Medicine (MED)
dc.subjectCLINICAL MEDICINE
dc.subjectHEMATOLOGY
dc.subjectONCOLOGY
dc.subjectAdjuvant therapy
dc.subjectDisease-free survival
dc.subjectOsteosarcoma
dc.subjectOverall survival
dc.titlePrognostic Factors Associated with Resected Osteosarcoma: Efficacy of Adjuvant Setting, Real-World Experience
dc.typearticle
dspace.entity.typePublication
local.avesis.idf0992c49-c593-4742-b11c-a98212ddba5c
local.indexed.atSCOPUS
relation.isAuthorOfPublication62dc4129-dd1f-4b3b-b128-57f2e95bf2d4
relation.isAuthorOfPublication6b4118fa-7c40-4624-8d36-2f74546b0e2c
relation.isAuthorOfPublication94f2cc20-98e7-49cd-81a8-9676400da4fc
relation.isAuthorOfPublication7499614e-1a5f-4d03-b07e-d9d208d3c90e
relation.isAuthorOfPublication22952072-1852-47c4-b1ff-669ac16d2ad6
relation.isAuthorOfPublication0bbf9e5a-bf3e-4645-9f2d-1e1de92915d0
relation.isAuthorOfPublicationd4f139e7-cf36-415c-a82e-a9c7956ecede
relation.isAuthorOfPublication45c34df1-af1e-4065-bd94-a363edfac03a
relation.isAuthorOfPublication.latestForDiscovery62dc4129-dd1f-4b3b-b128-57f2e95bf2d4

Files

Collections

Research Outputs